PNEUMOCOCCAL SEROTYPE 1 MENINGITIS OUTBREAK IN BRONG AHAFO REGION, THREE YEARS AFTER THE IMPLEMENTATION OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN GHANA

2016 ◽  
Author(s):  
Brenda Kwambana
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Serotype 1 ◽  
Pneumococcal Serotype ◽  
Brong Ahafo Region ◽  
Brong Ahafo

13-valent pneumococcal conjugate vaccine immune sera protects against pneumococcal serotype 1, 3, and 5 bacteremia in a neonatal rat challenge model

2011 ◽  
Vol 7 (sup1) ◽  
pp. 75-84 ◽  
Author(s):  
Philip Fernsten ◽  
Kathryn W. Mason ◽  
Xinhong Yu ◽  
Donna Tummolo ◽  
Kelly A. Belanger ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Neonatal Rat ◽  
Serotype 1 ◽  
Pneumococcal Serotype

scholarly journals Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays?

Vaccines ◽  
2019 ◽  
Vol 7 (1) ◽  
pp. 4 ◽  
Author(s):  
Ezra Linley ◽  
Abigail Bell ◽  
Jenna F. Gritzfeld ◽  
Ray Borrow
Keyword(s):  
Conjugate Vaccine ◽  
Invasive Pneumococcal Disease ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Disease ◽  
Capsular Polysaccharide ◽  
Multiplex Assay ◽  
Limited Efficacy ◽  
The Future ◽  
Pneumococcal Serotype

Since the introduction of the 13-valent pneumococcal conjugate vaccine, a number of studies have demonstrated the limited efficacy of the pneumococcal serotype 3 component of this vaccine. Evidence from seven countries (Denmark, France, Greece, Portugal, Sweden, UK, US) shows limited or no effectiveness of the 13-valent pneumococcal conjugate vaccine against serotype 3 invasive pneumococcal disease and carriage. The serotype 3 capsule has some unique characteristics that may serve to explain this lack of efficacy—capsular polysaccharide is abundantly expressed, leading to a greater thickness of capsule, and free capsular polysaccharide may be released during growth. The serotype 3 component of the Luminex multiplex assay demonstrates inferior inter-laboratory reproducibility than other components and results may not be reliable. This communication outlines this evidence and discusses whether it is necessary to include serotype 3 in the assay in the future.

scholarly journals Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine

PLoS ONE ◽  
2022 ◽  
Vol 17 (1) ◽  
pp. e0262225
Author(s):  
Sweta M. Patel ◽  
Yazdani B. Shaik-Dasthagirisaheb ◽  
Morgan Congdon ◽  
Rebecca R. Young ◽  
Mohamed Z. Patel ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Invasive Pneumococcal Disease ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Disease ◽  
Conjugate Vaccines ◽  
Vaccine Serotypes ◽  
Vaccine Introduction ◽  
Molecular Serotyping ◽  
Sustained Effect ◽  
Pneumococcal Serotype

Pneumococcal conjugate vaccines reduce the burden of invasive pneumococcal disease, but the sustained effect of these vaccines can be diminished by an increase in disease caused by non-vaccine serotypes. To describe pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine (PCV-13) in July 2012, we performed molecular serotyping of 268 pneumococcal strains isolated from 221 children between 2012 and 2017. The median (interquartile range) age of the children included in this analysis was 6 (3,12) months. Fifty-nine percent of the children had received at least one dose of PCV-13 and 35% were fully vaccinated with PCV-13. While colonization by vaccine serotypes steadily declined following PCV-13 introduction, 25% of strains isolated more than 3 years after vaccine introduction were PCV-13 serotypes. We also observed an increase in colonization by non-vaccine serotypes 21 and 23B, which have been associated with invasive pneumococcal disease and antibiotic resistance in other settings.

Increased incidence of serotype-1 invasive pneumococcal disease in young female adults in The Netherlands

2013 ◽  
Vol 142 (9) ◽  
pp. 1996-1999 ◽  
Author(s):  
S. P. VAN MENS ◽  
A. M. M. VAN DEURSEN ◽  
S. C. A. MEIJVIS ◽  
B. J. M. VLAMINCKX ◽  
E. A. M. SANDERS ◽  
...  
Keyword(s):  
The Netherlands ◽  
Conjugate Vaccine ◽  
Invasive Pneumococcal Disease ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Disease ◽  
Young Female ◽  
Age Group ◽  
Immunization Schedule ◽  
National Immunization ◽  
Serotype 1

SUMMARYAnalysis of the Dutch national invasive pneumococcal disease (IPD) surveillance data by sex reveals an increase in the incidence of serotype-1 disease in young female adults in The Netherlands after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in the national immunization schedule. This has led to an overall increase in IPD in women aged 20–45 years, which was not observed in men of the same age. No other differences in serotype shifts possibly induced by the introduction of PCV7 were observed between the sexes in this age group. Serotype 1 is a naturally fluctuating serotype in Europe and it has been associated with disease in young healthy adults before. It remains uncertain whether or not there is an association between the observed increase in serotype-1 disease in young female adults and the implementation of PCV7 in The Netherlands.

Sign in / Sign up

Export Citation Format

Share Document